특허 및 논문

바이오솔빅스에 자료실을 확인해 보세요.
bt_bb_section_bottom_section_coverage_image

BIOSOLVIX ARCHIVE특허 및 논문

Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization  international pharmacov

작성자
관리자
작성일
2024-02-01 22:07
조회
238

Jung SY, Kim MS, Li H, Lee KH, Koyanagi A, Solmi M, Kronbichler A, Dragioti E, Tizaoui K, CargninS, Terrazzino S, Hong SW, Ghayda RA, Kim NK, Chung SK, Jacob L, Salem JE, Yon DK, Lee SW, Kostev K, Kim AY, Jung JW, Choi JY, Shin JS, Park

SJ, Choi SW, Ban K, Moon SH, Go YY, Shin JI, Smith L. Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization  international pharmacovigilance database. Clinical and Translational Science

2022;15:501–513.


Abstract



On October 2020, the US Food and Drug Administration (FDA) approved remdesivir as the first drug for the treatment of coronavirus disease 2019 (COVID-19), increasing remdesivir prescriptions worldwide. However, potential cardiovascular (CV) toxicities associated with remdesivir remain unknown. We aimed to characterize the CV adverse drug reactions (ADRs) associated with remdesivir using VigiBase, an individual case safety report database of the World Health Organization (WHO). Disproportionality analyses of CV-ADRs associated with remdesivir were performed using reported odds ratios and information components. We conducted in vitro experiments using cardiomyocytes derived from human pluripotent stem cell cardiomyocytes (hPSC-CMs) to confirm cardiotoxicity of remdesivir. To distinguish drug-induced CV-ADRs from COVID-19 effects, we restricted analyses to patients with COVID-19 and found that, after adjusting for multiple confounders, cardiac arrest (adjusted odds ratio [aOR]: 1.88, 95% confidence interval [CI]: 1.08–3.29), bradycardia (aOR: 2.09, 95% CI: 1.24–3.53), and hypotension (aOR: 1.67, 95% CI: 1.03–2.73) were associated with remdesivir. In vitro data demonstrated that remdesivir reduced the cell viability of hPSC-CMs in time- and dose-dependent manners. Physicians should be aware of potential CV consequences following remdesivir use and implement adequate CV monitoring to maintain a tolerable safety margin.


 

논문확인(클릭시이동)
전체 52
번호 제목 작성자 작성일 추천 조회
42
Multiple isogenic GNE-myopathy modeling with mutation specific phenotypes from human pluripotent stem cells by base editors.
관리자 | 2024.02.02 | 추천 0 | 조회 232
관리자 2024.02.02 0 232
41
In silico design and fabrication of an SFI chip-based microspheroid culture system.
관리자 | 2024.02.02 | 추천 0 | 조회 290
관리자 2024.02.02 0 290
40
Effect and application of cryopreserved three-dimensional microcardiac spheroids in myocardial infarction therapy
관리자 | 2024.02.01 | 추천 0 | 조회 231
관리자 2024.02.01 0 231
39
Blue laser-induced selective vasorelaxation by the activation of NOSs.
관리자 | 2024.02.01 | 추천 0 | 조회 241
관리자 2024.02.01 0 241
38
Therapeutic Efficacy of Artificial Skin Produced by 3D Bioprinting.
관리자 | 2024.02.01 | 추천 0 | 조회 267
관리자 2024.02.01 0 267
37
Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization  international pharmacov
관리자 | 2024.02.01 | 추천 0 | 조회 238
관리자 2024.02.01 0 238
36
Predicting in vivo therapeutic efficacy of bioorthogonally labeled endothelial progenitor cells in hind limb ischemia models vi
관리자 | 2024.02.01 | 추천 0 | 조회 228
관리자 2024.02.01 0 228
35
Application of co-culture technology of epithelial type cells and mesenchymal type cells using nanopatterned structures
관리자 | 2024.02.01 | 추천 0 | 조회 264
관리자 2024.02.01 0 264
34
Development of genetic quality tests for good manufacturing practice-compliant induced pluripotent stem cells and their derivat
관리자 | 2024.02.01 | 추천 0 | 조회 288
관리자 2024.02.01 0 288
33
Antiviral activity and safety of remdesivir against SARS-CoV- 2 infection in human pluripotent stem cell-derived cardiomyocytes
관리자 | 2024.02.01 | 추천 0 | 조회 248
관리자 2024.02.01 0 248